PDF(Pubmed)
Abstract：
BACKGROUND: Sarculator is a validated nomogram designed to predict overall survival (OS) in extremity soft tissue sarcoma (STS). Inflammation plays a critical role in cancer development and progression. There were no reports which investigated the relationship between Sarculator and inflammation.
METHODS: A total of 217 patients with extremity STS were included. The Sarculator-predicted 10-year probability of OS (pr-OS) was stratified into two subgroups: lower risk (10-year pr-OS ≥ 60%) and higher risk (10-year pr-OS < 60%). The modified Glasgow prognostic score (mGPS) varied from 0 to 2.
RESULTS: Out of the 217 patients, 67 were classified as higher risk, while 150 were lower risk. A total of 181 patients had an mGPS of 0, and 36 had a score of 1 or 2. The 5-year OS was 83.3%. When patients were divided into two groups according to the 10-year pr-OS, those with a higher risk had poorer OS than those with a lower risk. Among the patients with a higher risk, those with an mGPS of 1 or 2 had poorer OS compared to those with a score of 0.
CONCLUSIONS: The mGPS could potentially play an important role in identifying patients who are at high risk of death and metastasis in the higher-risk group on the Sarculator.
METHODS: A total of 217 patients with extremity STS were included. The Sarculator-predicted 10-year probability of OS (pr-OS) was stratified into two subgroups: lower risk (10-year pr-OS ≥ 60%) and higher risk (10-year pr-OS < 60%). The modified Glasgow prognostic score (mGPS) varied from 0 to 2.
RESULTS: Out of the 217 patients, 67 were classified as higher risk, while 150 were lower risk. A total of 181 patients had an mGPS of 0, and 36 had a score of 1 or 2. The 5-year OS was 83.3%. When patients were divided into two groups according to the 10-year pr-OS, those with a higher risk had poorer OS than those with a lower risk. Among the patients with a higher risk, those with an mGPS of 1 or 2 had poorer OS compared to those with a score of 0.
CONCLUSIONS: The mGPS could potentially play an important role in identifying patients who are at high risk of death and metastasis in the higher-risk group on the Sarculator.
摘要：
背景：Sarculator是一种经过验证的列线图，旨在预测四肢软组织肉瘤（STS）的总生存期（OS）。炎症在癌症的发展和进展中起着至关重要的作用。没有研究Sarculator与炎症之间关系的报告。
方法：纳入217例四肢STS患者。Sarculator预测的10年OS概率（pr-OS）分为两个亚组：风险较低（10年pr-OS≥60％）和风险较高（10年pr-OS<60％）。改良的格拉斯哥预后评分（mGPS）从0到2不等。
结果：在217名患者中，67人被归类为高风险，而150则风险较低。共有181名患者的mGPS为0，36名患者的评分为1或2。5年OS为83.3%。当患者根据10年pr-OS分为两组时，风险较高的患者的OS比风险较低的患者差.在风险较高的患者中，与评分为0的那些相比,mGPS为1或2的那些患者的OS较差.
结论：mGPS可能在鉴别谁是高危人群死亡和转移的患者中发挥重要作用。
方法：纳入217例四肢STS患者。Sarculator预测的10年OS概率（pr-OS）分为两个亚组：风险较低（10年pr-OS≥60％）和风险较高（10年pr-OS<60％）。改良的格拉斯哥预后评分（mGPS）从0到2不等。
结果：在217名患者中，67人被归类为高风险，而150则风险较低。共有181名患者的mGPS为0，36名患者的评分为1或2。5年OS为83.3%。当患者根据10年pr-OS分为两组时，风险较高的患者的OS比风险较低的患者差.在风险较高的患者中，与评分为0的那些相比,mGPS为1或2的那些患者的OS较差.
结论：mGPS可能在鉴别谁是高危人群死亡和转移的患者中发挥重要作用。
